Oncosnacks 14: Bevacizumab Toxicity (Part 1)
In many parts of the world, Bevacizumab is an important component of the treatment of glioblastoma, colorectal, hepatocellular and ovarian cancers. However, with such widespread use inevitably comes toxicity. Side effects related to bevacizumab are not your garden-variety chemotherapy side effects, nor are they similar to toxicity from immunotherapy. Rather, they stand apart, unique amongst our systemic therapies.
In their latest Onconack, Josh and Michael take a look at two of the most commonly described toxicities related to bevacizumab: hypertension and proteinuria. This is sure to be a valuable resource to any oncology trainee blessed (or cursed) with the unit pager!
Links to useful sources for further reading (subscription may be required):
Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. https://doi.org/10.1136/esmoopen-2019-000605
Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. https://pubmed.ncbi.nlm.nih.gov/25568148/
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. https://www.nejm.org/doi/10.1056/NEJMoa1104390?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938590/
